Sign in

edreznik.bsky.social

@edreznik.bsky.social
152 followers 34 following 11 posts
PostsRepliesMedia
Reposted by @edreznik.bsky.social
Marcus Goncalves @marcusgon.bsky.social · 30/09/2025
The largest description of cancer #cachexia to date across all tumor types and over time using data from 60,000 people. @edreznik.bsky.social redefines what we know about human cachexia integrating genetics, lab values, and treatment lines. www.medrxiv.org/content/10.1...
medrxiv.org
A health-system-scale, episode-resolved multimodal atlas of cancer cachexia
Cancer cachexia is a wasting syndrome with outsized impact on morbidity and mortality. Neither the etiology of cachexia, nor its consequences on patient physiology and outcomes, are well-understood. H...
021
Reposted by @edreznik.bsky.social
Payam Gammage @mito-oncogene.bsky.social · 03/11/2025
Excited to share our latest work in collaboration with the @edreznik.bsky.social lab @mskcancercenter.bsky.social, where we describe functionally dominant mitochondrial DNA mutations in patient tumors. So, what is functional dominance in mitochondrial genetics, I hear you ask? rdcu.be/eN1jm
rdcu.be
Functionally dominant hotspot mutations of mitochondrial ribosomal RNA genes in cancer
Nature Genetics - Analysis of 14,106 tumor genomes highlights recurrent mutations in mitochondrial ribosomal RNA encoded within the mitochondrial genome. Mutations occur at hotspot positions and...
16823
edreznik.bsky.social @edreznik.bsky.social · 08/08/2025
For those of you hunting for your next position, please consider applying for a postdoctoral position in our lab. Our science is wild and exciting, and I promise to train and feed (yes, w/free food) you well. It doesn't hurt that we are on a publication hot streak.
021
Reposted by @edreznik.bsky.social
Nature Cancer @natcancer.nature.com · 18/04/2025
🚨New Review available online Scott M. Haake and colleagues provide an overview of recent research on biomarkers to predict immunotherapy response in clear cell renal cell carcinoma and discuss the predictive and prognostic biomarkers to prioritize in this context. www.nature.com/articles/s43...
nature.com
Biomarker-informed care for patients with renal cell carcinoma - Nature Cancer
Haake and colleagues provide an overview of recent research on biomarkers to predict immunotherapy response in clear cell renal cell carcinoma and discuss the predictive and prognostic biomarkers to p...
083
Reposted by @edreznik.bsky.social
Nature Cancer @natcancer.nature.com · 18/04/2025
🌟Technical Report online now Amy Xie, Wesley Tansey & Ed Reznik present the tool UnitedMet that imputes metabolite levels from transcriptomic data, and find oxidative phosphorylation associated with both BAP1 status and metastasis or therapy outcome in kidney cancer. www.nature.com/articles/s43...
nature.com
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples - Nature Cancer
Xie et al. present UnitedMet, a tool that leverages RNA–metabolite covariation to impute metabolite levels from transcriptomic data, and find oxidative phosphorylation associated with both BAP1 status...
062
edreznik.bsky.social @edreznik.bsky.social · 18/04/2025
Joint work with Wesley Tansey and the med-school-bound Amy Xie.
000
edreznik.bsky.social @edreznik.bsky.social · 18/04/2025
Excited to tell you about a new method from our lab, UnitedMet, which imputes metabolite levels/ isotope tracing from RNA data. It features the best first sentence I've ever written: "Comprehensively studying metabolism requires metabolite measurements." www.nature.com/articles/s43...
nature.com
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples - Nature Cancer
Xie et al. present UnitedMet, a tool that leverages RNA–metabolite covariation to impute metabolite levels from transcriptomic data, and find oxidative phosphorylation associated with both BAP1 status...
100
Reposted by @edreznik.bsky.social
Christian Frezza @frezzalab.bsky.social · 29/01/2025
Really cool work from @zampierilab.bsky.social Congratulations all!! www.nature.com/articles/s41...
nature.com
A human metabolic map of pharmacological perturbations reveals drug modes of action - Nature Biotechnology
Mapping the metabolic effects of drugs helps define their mode of action.
0244
Reposted by @edreznik.bsky.social
Payam Gammage @mito-oncogene.bsky.social · 14/01/2025
Really pumped to see our paper on how mtDNA mutations modify tumour biology with @edreznik.bsky.social & colleagues highlighted by the US National Cancer Institute’s Division of Cancer Biology as one of their advances of 2024! If you’re interested do check it out 😊 www.cancer.gov/about-nci/or...
cancer.gov
Research Advances in Cancer Biology
Research projects funded by the Division of Cancer Biology have led to many new discoveries and advances in basic cancer research that continue to lay the groundwork for future clinical breakthroughs ...
042
Reposted by @edreznik.bsky.social
edreznik.bsky.social @edreznik.bsky.social · 18/12/2024
A culmination of ~5 years of work, today our work on biallelic alterations across tumor suppressor genes is published in @cellcellpress.bsky.social With Mark Zucker, Maria Perry, and Chai Bandlamudi www.cell.com/cell/fulltex...
cell.com
Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer
Selective pressure for biallelic inactivation varies widely across tumor suppressor genes and is a biomarker for therapeutic response, providing new insights into Knudson’s two-hit hypothesis.
101
edreznik.bsky.social @edreznik.bsky.social · 18/12/2024
This work, as with all of our work, is the product of a community. It's the collective result of the bravery of our patients, of the many conversations (with our colleagues, trainees) and collaborations (with our clinicians), and the power and joy of revisiting scientific dogma
000
edreznik.bsky.social @edreznik.bsky.social · 18/12/2024
Those re-classified VUSs have significant clinical implications. Believe it or not: biallelical loss of (VUS or driver) KEAP1 is a predictive biomarker of inferior response in LUAD. Monoallelic loss (VUS or driver!) effectively WT. Zygosity itself matters.
100
edreznik.bsky.social @edreznik.bsky.social · 18/12/2024
Selection for biallelic inactivation is also translationally useful for classifying variants of unknown significance. Look at all those VUSs in KEAP1 that are functional, as validated by a base editing screen with Francisco Sanchez-Rivera and Sam Gould
100
edreznik.bsky.social @edreznik.bsky.social · 18/12/2024
Selection for biallelic inactivation is itself a highly useful metric for identifying cryptic driver mutations. APC is a rare driver in lung and prostate cancers
100
edreznik.bsky.social @edreznik.bsky.social · 18/12/2024
Quantifying selective pressure for biallelic inactivation, we found that genes assorted in four classes based on the prevalence of selection across diseases. Class I universally selected, but many of our favorite genes (ARID1A, PIK3R1) in Class 2/3/4
100
edreznik.bsky.social @edreznik.bsky.social · 18/12/2024
We provide a foundational but missing piece of data for the field at large: a resource of how often, and in what manner, genes are biallelically inactivated. Couldn't google it before, now you can. There's lots of heterogeneity across genes, and also within genes across diseases.
100
edreznik.bsky.social @edreznik.bsky.social · 18/12/2024
The goal was to assess the selective pressure for, and functional consequences of, biallelic activation in TSGs across our prospective clinical sequencing cohort. Unexpectedly (and so therefore, expectedly), things were not as expected. Two hit hypothesis be damned!
100
edreznik.bsky.social @edreznik.bsky.social · 18/12/2024
A culmination of ~5 years of work, today our work on biallelic alterations across tumor suppressor genes is published in @cellcellpress.bsky.social With Mark Zucker, Maria Perry, and Chai Bandlamudi www.cell.com/cell/fulltex...
cell.com
Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer
Selective pressure for biallelic inactivation varies widely across tumor suppressor genes and is a biomarker for therapeutic response, providing new insights into Knudson’s two-hit hypothesis.
101